How have RNUGF shares performed in 2024?

ReNeuron Group's stock was trading at $0.0515 at the beginning of the year. Since then, RNUGF shares have decreased by 97.9% and is now trading at $0.0011. View the best growth stocks for 2024 here .

How do I buy shares of ReNeuron Group?

Shares of RNUGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:RNUGF

ReNeuron Group (RNUGF) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free RNUGF Stock Alerts

$0.0011

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.0011
▼
$0.0011
50-Day Range: $0.00
▼
$0.05
52-Week Range: $0.00
▼
$0.05

Volume: N/A
Average Volume: 126 shs
Market Capitalization: $62,887.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get ReNeuron Group alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About ReNeuron Group Stock (OTCMKTS:RNUGF)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

RNUGF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RNUGF Stock News Headlines

October 18, 2023 | investing.com

Rugvista Group AB (RUG)

April 3, 2023 | proactiveinvestors.com

ReNeuron appoints new scientific advisory board

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 17, 2023 | proactiveinvestors.com

ReNeuron has extended cash runway as it focuses on validating its exosome platform

December 8, 2022 | proactiveinvestors.com

ReNeuron says positive iPSC data presented at conference

December 8, 2022 | proactiveinvestors.com

ReNeuron Group says positive iPSC data presented at conference

December 2, 2022 | proactiveinvestors.com

ReNeuron unveils jump in revenue for first-half of 2022; issues a funding update

November 3, 2022 | finance.yahoo.com

ReNeuron Group (RENE): Re-initiation - Rebranding in Exosome Targeted Drug Delivery

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 14, 2022 | markets.businessinsider.com

ReNeuron Group Names John Hawkins CFO - Quick Facts

See More Headlines

Receive RNUGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:RNUGF
Previous Symbol: NASDAQ:RNUGF
CUSIP: N/A
CIK: N/A
Web: www.reneuron.com
Phone: 44-20-3819-8400
Fax: N/A
Employees: 26
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 1.51
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $640,000.00
Price / Sales: 0.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 0.01

Miscellaneous

Outstanding Shares: 57,170,000
Free Float: N/A
Market Cap: $62,887.00
Optionable: Not Optionable
Beta: 0.52

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Iain Gladstone Ross B.Sc. (Age 70)
BSc (Hons), C.DIR, CH.D, Executive Chairman
Comp: $542.99k
Mr. John Michael Hawkins A.C.A. (Age 58)
Company Secretary, CFO & Director
Comp: $243.6k
Dr. John David Sinden B.A. (Age 73)
BA, M.A., MA, Ph.D., Co-Founder
Comp: $130.06k
Ms. Suzanne Hancock
Chief Operations Officer
Dr. Randolph Corteling Ph.D.
Chief Scientific Officer
Mr. Simon Dew
Chief Business Officer

Key Competitors

View All Competitors

RNUGF Stock Analysis - Frequently Asked Questions

How have RNUGF shares performed in 2024?: ReNeuron Group's stock was trading at $0.0515 at the beginning of the year. Since then, RNUGF shares have decreased by 97.9% and is now trading at $0.0011.
View the best growth stocks for 2024 here.
How do I buy shares of ReNeuron Group?: Shares of RNUGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RNUGF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial